N. B. Finnerup, N. Attal, and S. Haroutounian, Pharmacotherapy for Neuropathic Pain in Adults: A Systematic Review and Meta-Analysis, Journal of Vascular Surgery, vol.62, issue.4, p.1091, 2015.

D. L. Hershman, C. Lacchetti, and C. L. Loprinzi, Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary, Journal of Oncology Practice, vol.10, issue.6, pp.e421-e424, 2014.

, Guideline Summary: Use of Epoetin and Darbepoetin in Patients With Cancer?2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update, Journal of Oncology Practice, vol.4, issue.1, pp.48-52, 2008.

M. Selvy, M. Cuménal, N. Kerckhove, C. Courteix, J. Busserolles et al., The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials, Expert Opinion on Drug Safety, vol.19, issue.6, pp.707-733, 2020.
URL : https://hal.archives-ouvertes.fr/hal-02997564

M. J. Brownstein, A brief history of opiates, opioid peptides, and opioid receptors., Proceedings of the National Academy of Sciences, vol.90, issue.12, pp.5391-5393, 1993.

, Meselson-Radding Model Of Recombination (1975 Proc Natl Acad Sci USA 72:358), Proc Natl Acad Sci USA, vol.90, pp.5391-5393

A. Rosenblum, L. A. Marsch, H. Joseph, and R. K. Portenoy, Opioids and the treatment of chronic pain: Controversies, current status, and future directions., Experimental and Clinical Psychopharmacology, vol.16, issue.5, pp.405-416, 2008.

K. N. Manchikanti,-ba, L. Manchikanti,-md, K. S. Damron,-rn, V. Pampati,-msc, and B. Fellows,-ma, Increasing deaths from opioid analgesics in the United States: An evaluation in an interventional pain management practice, Journal of Opioid Management, vol.4, issue.5, p.271, 2018.

H. Gallagher and D. Galvin, Opioids for chronic non-cancer pain, BJA Education, vol.18, issue.11, pp.337-341, 2018.

M. Karst, K. Salim, S. Burstein, I. Conrad, L. Hoy et al., Analgesic Effect of the Synthetic Cannabinoid CT-3 on Chronic Neuropathic Pain, JAMA, vol.290, issue.13, p.1757, 2003.

C. J. Mccartney, A. Sinha, and J. Katz, A Qualitative Systematic Review of the Role of N-Methyl-d-Aspartate Receptor Antagonists in Preventive Analgesia, Anesthesia & Analgesia, vol.5, pp.1385-1400, 2004.

B. Tena, C. Gomar, and J. Rios, Perioperative Epidural or Intravenous Ketamine Does Not Improve the Effectiveness of Thoracic Epidural Analgesia for Acute and Chronic Pain After Thoracotomy, The Clinical Journal of Pain, vol.30, issue.6, pp.490-500, 2014.

C. Dualé, F. Sibaud, V. Guastella, L. Vallet, Y. Gimbert et al., Perioperative ketamine does not prevent chronic pain after thoracotomy, European Journal of Pain, vol.13, issue.5, pp.497-505, 2009.

C. Mendola, G. Cammarota, and R. Netto, S(+)-ketamine for control of 12 perioperative pain and prevention of post thoracotomy pain syndrome: a 13 randomized, double-blind study, Minerva Anestesiol, vol.78, pp.757-766, 2012.

M. E. Lynch, A. J. Clark, J. Sawynok, and M. J. Sullivan, Topical 2% Amitriptyline and 1% Ketamine in Neuropathic Pain Syndromes, Anesthesiology, vol.103, issue.1, pp.140-146, 2005.

V. Morel, D. Joly, C. Villatte, C. Dubray, X. Durando et al., Memantine before Mastectomy Prevents Post-Surgery Pain: A Randomized, Blinded Clinical Trial in Surgical Patients, PLOS ONE, vol.11, issue.4, p.e0152741, 2016.

G. Schifitto, C. T. Yiannoutsos, D. M. Simpson, C. Marra, E. Singer et al., A placebo-controlled study of memantine for the treatment of human immunodeficiency virus?associated sensory neuropathy, Journal of NeuroVirology, vol.12, issue.4, pp.328-331, 2006.

K. Wiech, R. Kiefer, S. T??pfner, H. Preissl, C. Braun et al., A Placebo-Controlled Randomized Crossover Trial of the N-Methyl-d-Aspartic Acid Receptor Antagonist, Memantine, in Patients with Chronic Phantom Limb Pain, Anesthesia & Analgesia, vol.98, pp.408-413, 2004.

L. Nikolajsen, H. Gottrup, A. G. Kristensen, and T. S. Jensen:, Memantine (a N-methyl-d-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. (Danish Pain Research Center, University of Aarhus, Aarhus, Denmark) Anesth Analg 2000;91:960-966., Pain Practice, vol.1, issue.2, pp.204-205, 2001.

R. L. Schmid, A. N. Sandler, and J. Katz, Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes, Pain, vol.82, issue.2, pp.111-125, 1999.

M. Niesters, C. Martini, and A. Dahan, Ketamine for chronic pain: risks and benefits, British Journal of Clinical Pharmacology, vol.77, issue.2, pp.357-367, 2014.

M. S. Kurdi, K. A. Theerth, and R. S. Deva, Ketamine: Current applications in anesthesia, pain, and critical care, Anesthesia: Essays and Researches, vol.8, issue.3, p.283, 2014.

R. Kurian, K. Raza, and H. Shanthanna, A systematic review and meta?analysis of memantine for the prevention or treatment of chronic pain, European Journal of Pain, vol.2, pp.1234-1250, 2019.

P. Anand and K. Bley, Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch, British Journal of Anaesthesia, vol.107, issue.4, pp.490-502, 2011.

P. Anand and K. Bley, Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch, British Journal of Anaesthesia, vol.107, issue.4, pp.490-502, 2011.

A. Szallasi, T. Szabó, T. Bíró, S. Modarres, P. M. Blumberg et al., Resiniferatoxin-type phorboid vanilloids display capsaicin-like selectivity at native vanilloid receptors on rat DRG neurons and at the cloned vanilloid receptor VR1, British Journal of Pharmacology, vol.128, issue.2, pp.428-434, 1999.

, Book Reviews, Australian Journal of Psychology, vol.51, issue.3, pp.211-212, 1999.

S. Derry and R. A. Moore, Topical capsaicin (low concentration) for chronic neuropathic pain in adults, Cochrane Database of Systematic Reviews, p.10111, 2012.

S. Derry, A. S. Rice, P. Cole, T. Tan, and R. A. Moore, Topical capsaicin (high concentration) for chronic neuropathic pain in adults, Cochrane Database of Systematic Reviews, vol.1, p.7393, 2017.

K. Kulkantrakorn, C. Lorsuwansiri, and P. Meesawatsom, 0.025% Capsaicin Gel for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double-Blind, Crossover, Placebo-Controlled Trial, Pain Practice, vol.13, issue.6, pp.497-503, 2012.

K. Kulkantrakorn, A. Chomjit, P. Sithinamsuwan, T. Tharavanij, J. Suwankanoknark et al., 0.075% capsaicin lotion for the treatment of painful diabetic neuropathy: A randomized, double-blind, crossover, placebo-controlled trial, Journal of Clinical Neuroscience, vol.62, pp.174-179, 2019.

D. M. Simpson, J. Robinson-papp, J. Van, M. Stoker, H. Jacobs et al., Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study, The Journal of Pain, vol.18, issue.1, pp.42-53, 2017.

J. Heyde, Zwischen Preußen und Russland ? das 18. Jahrhundert, Geschichte Polens, vol.18, pp.42-53, 2017.

J. Moon, P. Lee, and Y. Kim, Efficacy and Safety of 0.625% and 1.25% 22 Capsaicin Patch in Peripheral Neuropathic Pain: Multi-Center, Randomized, and 23 Semi-Double Blind Controlled Study, Pain Physician, vol.20, pp.27-35, 2017.

M. J. Teixeira, L. M. Menezes, V. Silva, R. Galhardoni, J. Sasson et al., Liposomal topical capsaicin in post-herpetic neuralgia: a safety pilot study, Arquivos de Neuro-Psiquiatria, vol.73, issue.3, pp.237-240, 2015.

C. M. Campbell, E. Diamond, W. K. Schmidt, M. Kelly, R. Allen et al., A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton?s neuroma, PAIN, vol.157, issue.6, pp.1297-1304, 2016.

J. A. Paice, C. E. Ferrans, F. R. Lashley, S. Shott, V. Vizgirda et al., Topical Capsaicin in the Management of HIV-Associated Peripheral Neuropathy, Journal of Pain and Symptom Management, vol.19, issue.1, pp.45-52, 2000.

B. Frias and A. Merighi, Capsaicin, Nociception and Pain, Molecules, vol.21, issue.6, p.797, 2016.

R. Baron, M. Allegri, G. Correa-illanes, G. Hans, M. Serpell et al., The 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its Use, Pain and Therapy, vol.5, issue.2, pp.149-169, 2016.

J. Sawynok, Topical analgesics for neuropathic pain: Preclinical exploration, clinical validation, future development, European Journal of Pain, vol.18, issue.4, pp.465-481, 2013.

J. Sawynok, Topical analgesics for neuropathic pain: Preclinical exploration, clinical validation, future development, European Journal of Pain, vol.18, issue.4, pp.465-481, 2013.

A. Wehrfritzl, B. Namerl, H. Ihmsenl, C. Muellerl, J. Filitzl et al., Differential effects on sensory functions and measures of epidermal nerve fiber density after application of a lidocaine patch (5%) on healthy human skin, European Journal of Pain, vol.15, issue.9, pp.907-912, 2011.

S. Derry, P. J. Wiffen, E. A. Kalso, R. F. Bell, D. Aldington et al., Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews, Cochrane Database of Systematic Reviews, vol.8, p.8609, 2017.

M. Palladini, I. Boesl, S. Koenig, B. Buchheister, and N. Attal, Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial, Current Medical Research and Opinion, vol.35, issue.5, pp.757-766, 2019.

Y. Kim, A. M. Castañeda, C. Lee, H. Jin, K. S. Park et al., Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain, Regional Anesthesia and Pain Medicine, vol.43, issue.4, pp.415-424, 2018.

D. T. Demant, K. Lund, N. B. Finnerup, J. Vollert, C. Maier et al., Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype, PAIN, vol.156, issue.11, pp.2234-2244, 2015.

D. T. Demant, K. Lund, N. B. Finnerup, J. Vollert, C. Maier et al., Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype, PAIN, vol.156, issue.11, pp.2234-2244, 2015.

A. Binder, J. Bruxelle, P. Rogers, G. Hans, I. Bösl et al., Topical 5% Lidocaine (Lignocaine) Medicated Plaster Treatment for Post-Herpetic Neuralgia, Clinical Drug Investigation, vol.29, issue.6, pp.393-408, 2009.

A. L. Cheville, J. A. Sloan, D. W. Northfelt, A. P. Jillella, G. Y. Wong et al., Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB), Supportive Care in Cancer, vol.17, issue.4, pp.451-460, 2009.

K. Ho, B. K. Huh, W. D. White, C. Yeh, and E. Millerho, 41: Topical amitriptyline versus lidocaine in the treatment of neuropathic pain, Regional Anesthesia and Pain Medicine, vol.32, issue.5, pp.12-12, 2007.

L. Estanislao, K. Carter, J. Mcarthur, R. Olney, and D. Simpson, A Randomized Controlled Trial of 5% Lidocaine Gel for HIV-Associated Distal Symmetric Polyneuropathy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.37, issue.5, pp.1584-1586, 2004.

T. Meier, G. Wasner, M. Faust, T. Kuntzer, F. Ochsner et al., Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study, Pain, vol.106, issue.1, pp.151-158, 2003.

B. S. Galer, M. P. Jensen, T. Ma, P. S. Davies, and M. C. Rowbotham, The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study With Use of the Neuropathic Pain Scale, The Clinical Journal of Pain, vol.18, issue.5, pp.297-301, 2002.

J. Park and H. Park, Botulinum Toxin for the Treatment of Neuropathic Pain, Toxins, vol.9, issue.9, p.260, 2017.

D. Ranoux, N. Attal, F. Morain, and D. Bouhassira, Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain, Annals of Neurology, vol.64, issue.3, pp.274-283, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00292356

N. Attal, D. C. De-andrade, F. Adam, D. Ranoux, M. J. Teixeira et al., Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial, The Lancet Neurology, vol.15, issue.6, pp.555-565, 2016.

M. Ghasemi, M. Ansari, and K. Basiri, The effects of intradermal botulinum toxin 10 type a injections on pain symptoms of patients with diabetic neuropathy, J Res, p.11

, New Facts About Parasites, Scientific American, vol.111, issue.6, pp.106-106, 1914.

W. Chen, R. Yuan, S. Chiang, J. Sheu, J. Yu et al., OnabotulinumtoxinA Improves Tactile and Mechanical Pain Perception in Painful Diabetic Polyneuropathy, The Clinical Journal of Pain, vol.29, issue.4, pp.305-310, 2013.

R. Y. Yuan, J. J. Sheu, J. M. Yu, W. T. Chen, I. J. Tseng et al., Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial, Neurology, vol.72, issue.17, pp.1473-1478, 2009.

J. Wei, X. Zhu, G. Yang, J. Shen, P. Xie et al., The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta?analysis of randomized controlled trials, Brain and Behavior, vol.9, issue.10, p.1409, 2019.

D. Machado, A. L. Martimbianco, S. K. Bussadori, R. L. Pacheco, R. Riera et al., Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis, The Journal of Pain, vol.21, issue.3-4, pp.281-293, 2020.

Y. Dong, T. Wu, and X. Hu, Efficacy and safety of botulinum toxin type A for upper 24 limb spasticity after stroke or traumatic brain injury: a systematic review with 25 meta-analysis and trial sequential analysis, Eur J Phys Rehabil Med, vol.26, pp.256-267, 2017.

J. K. Jo, K. N. Kim, D. W. Kim, Y. T. Kim, J. Y. Kim et al., The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis, World Journal of Urology, vol.36, issue.2, pp.305-317, 2017.

J. Scholz, N. B. Finnerup, and N. Attal, The IASP classification of chronic pain for 31 ICD-11: chronic neuropathic pain, Pain, vol.160, pp.53-59, 2019.

N. Kerckhove, A. Collin, S. A. Condé, C. Chaleteix, D. Pezet et al., Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review, Frontiers in Pharmacology, vol.8, p.86, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01682157

H. Gaskell, R. A. Moore, S. Derry, and C. Stannard, Oxycodone for neuropathic pain and fibromyalgia in adults, 2014.

A. Vaz-carneiro and J. Costa, Analysis of the Cochrane Review: Incentives for Smoking Cessation. Cochrane Database Syst Rev. 2015;5:CD004307., Acta Médica Portuguesa, vol.29, issue.1, p.12, 2016.

S. Derry, R. Knaggs, P. J. Wiffen, C. Stannard, D. Aldington et al., Fentanyl for neuropathic pain in adults, 2015.

D. Libânio and L. F. Azevedo, Análise da Revisão Cochrane: Cromoscopia Versus Colonoscopia Convencional na Deteção de Pólipos ColoRetais. Cochrane Database Syst Rev. 2016;4:CD006439, Acta Médica Portuguesa, vol.29, issue.10, p.583, 2016.

T. E. Cooper, J. Chen, P. J. Wiffen, S. Derry, D. B. Carr et al., Morphine for chronic neuropathic pain in adults, Cochrane Database of Systematic Reviews, vol.5, p.11669, 2017.

R. M. Duehmke, S. Derry, P. J. Wiffen, R. F. Bell, D. Aldington et al., Tramadol for neuropathic pain in adults, Cochrane Database of Systematic Reviews, 2017.

M. Alves, M. B. Vieira, J. Costa, and A. V. Carneiro, Análise da Revisão Cochrane: Alta Hospitalar Precoce para Hospitalização Domiciliária. Cochrane Database Syst Rev. 2017;6:CD000356., Acta Médica Portuguesa, vol.30, issue.12, p.835, 2017.

, World Drug Report 2012, United Nations Office on Drugs and Crime. World drug report, 2012.

, Figure 6?source data 1. Pairwise information on imports of live swine from specific countries is available from 1996?2012., vol.9, p.464981

I. I. Michels, Behandlung einer Drogenabhängigkeit in Zentralasien und Umsetzung der WHO/UNODC International Standards of Treatment of Drug Use Disorders, Deutscher Suchtkongress 2017, 2017.

C. E. Grella and K. Lovinger, 30-Year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California, Drug and Alcohol Dependence, vol.118, issue.2-3, pp.251-258, 2011.

M. S. Cepeda, D. Fife, Q. Ma, and P. B. Ryan, Comparison of the Risks of Opioid Abuse or Dependence Between Tapentadol and Oxycodone: Results From a Cohort Study, The Journal of Pain, vol.14, issue.10, pp.1227-1241, 2013.

. Jensen, , 2006.

. Gimbel,

, Single Dose Ketanserin is Little Different from Placebo, InPharma, vol.551, issue.1, pp.16-16, 1986.

, Treatment-Emergent Adverse Event, 2020.

, Serious Adverse Event (SAE), 2014.